Similar articles

• [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].

  Heinzl S. Heinzl S. Med Monatsschr Pharm. 2000 Nov;23(11):350-2. Med Monatsschr Pharm. 2000. PMID: 11103587 German. No abstract available.
• Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

  Shak S. Shak S. Semin Oncol. 1999 Aug;26(4 Suppl 12):71-7. Semin Oncol. 1999. PMID: 10482196 Review.
• Trastuzumab in breast cancer.

  Katsumata M, Drebin JA, Greene MI. Katsumata M, et al. N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4. N Engl J Med. 2006. PMID: 16470952 No abstract available.
• Controversies in the use of adjuvant trastuzumab (Herceptin).

  Chowdhury S, Pickering L, Ellis P. Chowdhury S, et al. J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517. J Br Menopause Soc. 2006. PMID: 17178019 Review.
• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  Paik S, Kim C, Wolmark N. Paik S, et al. N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. N Engl J Med. 2008. PMID: 18367751 No abstract available.